You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses

Article metrics

Article menu

Download PDFPDF

XML
Short Report
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses

 

Online download statistics by month:

Online download statistics by month: December 2019 to October 2024

AbstractFullPdf
Dec 2019331
Jan 202030302
Feb 202018182
Mar 2020393912
Apr 2020525252
May 2020535311
Jun 2020545429
Jul 2020252517
Aug 20204949146
Sep 2020515161
Oct 2020494945
Nov 2020636339
Dec 2020686848
Jan 2021525239
Feb 2021717161
Mar 2021939372
Apr 2021808052
May 2021575752
Jun 2021585837
Jul 2021494937
Aug 2021585833
Sep 2021787844
Oct 2021707058
Nov 2021727251
Dec 2021999939
Jan 2022656841
Feb 2022474835
Mar 202214515043
Apr 202215215237
May 202212412628
Jun 2022768132
Jul 2022959822
Aug 2022748230
Sep 2022747414
Oct 2022808533
Nov 202213313455
Dec 2022909025
Jan 2023949526
Feb 2023454616
Mar 202310610627
Apr 2023777924
May 2023838316
Jun 2023707014
Jul 2023969836
Aug 2023707010
Sep 2023626215
Oct 2023838318
Nov 2023909320
Dec 202311711721
Jan 2024959532
Feb 2024767721
Mar 2024737630
Apr 2024414323
May 2024595932
Jun 2024424224
Jul 2024787821
Aug 2024535318
Sep 2024474822
Oct 2024474629
Total415041981930